GEN Exclusives

More »

GEN News Highlights

More »
Jul 27, 2009

BioFocus DPI and Oncodesign Ally to Provide Oncology Drug Discovery Services

  • BioFocus DPI and Oncodesign are pooling their respective expertise to provide clients with oncology drug discovery services. The partnership will leverage BioFocus’ target discovery and screening technologies, Oncodesign’s experimental pharmacology and biomarker design capabilities, as well as both companies’ complementary medicinal chemistry expertise.

    The alliance emerged in response to the industry’s growing knowledge of disease pathways and resulting need for specialized drug discovery services, comments Chris Newton, svp at BioFocus DPI. “Oncodesign’s extensive experience in developing anticancer therapeutics complements BioFocus DPI’s medicinal chemistry and biology expertise, creating a focused oncology drug discovery offering that can move rapidly from hit-finding to preclinical candidate.”
     
    U.K.-based BioFocus DPI is the drug discovery services division of Galapagos and offers fully integrated drug and target discovery services along with assay development and screening, compound libraries, structural biology expertise, in silico drug discovery, medicinal chemistry, ADME/PK capabilities, and compound management services. Based in France, Oncodesign is a specialist oncology preclinical CRO, offering a suite of discovery services along with preclinical, translational, and clinical research up to Phase I/IIb trials.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?